UNSPSC 51384509: Ibuprofen

This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WK2XYI10QM, chemically known as u-18,573 but generally known as ibuprofen, which bears US NIH Compound Identifier 3672. European Medicines Agency schedules Ibuprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08098MIG. The term IBUPROFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7).

UNSPSC 51384509 Ibuprofen is a Commodity code that nominally covers over-the-counter pain relievers, but recent state and local solicitations tagged under this code actually target broader pharmaceutical procurement—including naloxone, generic multi-source drugs, and over-the-counter products distributed through state and local health systems, cooperative purchasing alliances, and community health initiatives. State and local governments soliciting under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing vehicles. Seminole County, Florida and the Texas Health and Human Services Commission represent the issuing-body types active in recent opportunities; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, demonstrates how cooperative purchasing structures aggregate demand across multiple states and localities for pharmaceutical supply contracts.

Geographic activity centers on Florida, Texas, and Minnesota, with Oregon participating in the MMCAP cooperative. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023), which seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026), an exploratory market-intelligence notice gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers—AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson—with pricing weighted 75 percent on competitiveness and contract start-date of July 1, 2026. The mismatch between the code's nominal scope (ibuprofen) and the actual procurement activity (naloxone, generic drugs, OTC products, and direct-to-manufacturer initiatives) signals that this code carries limited specificity for ibuprofen-specific opportunities in current state and local procurement.